Results 11 to 20 of about 2,963,117 (406)
A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Journal of Hepatology, 2023 The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language.
M. Rinella +52 more
semanticscholar +2 more sources
陆军军医大学学报, 2023 Objective To explore the effect and molecular mechanism of artesunate (ART) on cholestatic liver fibrosis induced by 3, 5-diethoxycarbonyl-1, 4-dihydro-2, 4, 6-collidine (DDC).
TANG Wan +3 more
doaj +1 more source
Hepatology, 2023 Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach.
Z. Younossi +5 more
semanticscholar +1 more source
陆军军医大学学报, 2023 Objective To screen and verify the Hub genes involved in conjugated bile acid-induced hepatocyte metabolism through transcriptome sequencing analysis. Methods Primary mouse hepatocytes were treated with taurocholic acid (TCA), and the gene expression of ...
ZHANG Mengni +4 more
doaj +1 more source
Frontiers in Nutrition, 2022 Recent studies have revealed that sarcopenia is closely associated with obesity and non-alcoholic steatohepatitis (NASH). However, few attempted to explore the cause-and-effect relationship between sarcopenic obesity and NASH.
Zi-Xuan Wang +9 more
doaj +1 more source
Fatty liver index associates with relative sarcopenia and GH/ IGF- 1 status in obese subjects [PDF]
, 2016 Recently the association between hepatic steatosis and sarcopenia has been described. GH/IGF-1 axis has been postulated to play a role in linking fatty liver and low muscle mass.
Donini, Lorenzo Maria +5 more
core +4 more sources
Carrier-free curcumin nanoassemblies for enhancing therapy effects in inflammation related disease
Materials & Design, 2022 Hyperinflammation can lead to tissue injury, organ failure, and even fatalities by overproducing proinflammatory cytokines. The long-term safety and outstanding anti-inflammatory ability of natural products have attracted much attention, but the low ...
Liangjun Zhang +9 more
doaj +1 more source
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis [PDF]
Clinical and Molecular Hepatology, 2023 Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD) characterized by steatosis-associated inflammation and liver injury. Without effective treatment or management, NASH can have life-threatening outcomes.
Yi-wen Shi, Jian-Gao Fan
doaj +1 more source
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Frontiers in Endocrinology, 2023 Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders.
L. Rong +6 more
semanticscholar +1 more source
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
New England Journal of Medicine, 2021 BACKGROUND The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined.
A. Sanyal +16 more
semanticscholar +1 more source